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The observation by Jacobson et al. in 1957 that the rise of plasma erythropoietin 
(EPO) levels in rodents is severely blunted following bilateral nephrectomy’ has 
drawn attention to the important role of the kidneys in EPO formation. Continuing 
EPO production, however, albeit at a reduced level in adult anephric 
and the observation that anephric fetal and neonatal animals can produce as much 
EPO as unoperated ones4v5 provides evidence for the existence of extrarenal EPO 
formation. The investigation of EPO production in hepatectomized animals identi- 
fied the liver as the primary extrarenal site of EPO s y n t h e ~ i s . ~ * ~  Much of the 
evidence, however, regarding the role of the liver for EPO production in vivo has 
been indirect inasmuch as it was drawn from experiments in organ-ablated animals 
and because the demonstration of EPO production mostly depended upon bioas- 
says that were not specific for EPO or the use of antibodies raised against impure 
preparations of the hormone. More recently, direct demonstration of EPO gene 
expression, either by determination of EPO mRNA in tissue homogenates or by 
in situ hybridization on histological specimens, has allowed these studies to be 
extended and has not only confirmed a significant role of the liver in EPO produc- 
tion, but has also contributed to understanding of hepatic EPO formation at the 
cellular level. In this paper we will try to provide a brief overview of the knowledge 
that has accumulated and summarize some of our own work on EPO production 
by liver cells in viuo and in vitro. 
CONTRIBUTION OF THE LIVER TO EPO FORMATION IN VIVO 
In general, as in the kidneys, the major determinant of EPO production in the 
liver seems to be the oxygen content of blood. Thus, EPO hormone titers in 
anephric animals and hepatic EPO mRNA levels increase in response to reduction 
of either the oxygen carrying capacity or the oxygen saturation ~ fb lood .~ .*  Further- 
more, isolated perfused livers release EPO upon hypoxic per fu~ion .~  
The extent to which the oxygen-dependent production of EPO by the liver 
contributes to the total hormone production in the intact organism depends primar- 
ily on the developmental stage of the organism. A gradual “shift” of EPO produc- 
tion from liver to kidneys has been inferred from changes in the effect of nephrec- 
tomy and/or hepatectomy on EPO formation during development. The time of 
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this transition was found to be variable among different species. Thus, in sheep, 
bilateral nephrectomy, already during late gestation, reduced EPO production,I0 
whereas in rats, nephrectomy had no effect on EPO production for up to two 
weeks after birth.6*"-'3 In two studies, age-dependent changes in the contribution 
of liver and kidneys were demonstrated at the level of EPO I ~ R N A . ~ ~ , ' ~  These 
studies have also pointed to considerable species differences; in mice the kidneys 
were found to contain the majority of total EPO mRNA during late gestation and 
during all stages of postnatal development,14 whereas in rats, in accordance with 
organ ablation studies, the liver was found to contribute more than 50% to the 
total amount of EPO mRNA up to four weeks of age15 (FIG. 1). Furthermore, we 
found in rats that although the predominance shifts from liver to kidneys beyond 
this age, the total amount of EPO mRNA in the liver does not decrease with age 
but remains fairly constant, becoming less significant, only because the accumula- 
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FIGURE 1. Hepatic pro- 
portion of the total (sum of 
renal and hepatic) EPO 
mRNA in rats of various 
ages that were exposed for 
4 hours to normobaric hyp- 
oxia (mean ? SD, n = 7 for 
one-day old animals and 3 
for all other groups). EPO 
mRNA was quantified by 
RNase protection." 
- 
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tion of EPO mRNA in kidneys increases progressively." The mechanisms prevent- 
ing an increase in the production capacity for EPO in the liver, despite further 
growth of the organ, have not been resolved. 
In adults the liver has generally been considered to contribute no more than 
about 15% of EPO production, inasmuch as serum EPO levels were found to be 
reduced to such low levels following bilateral nephre~tomy.~ . '*"*~~ In intact ani- 
mals, however, under conditions of severe hypoxic or anemic hypoxia, the liver 
was found to contain at least as much EPO mRNA as one kidney, thus contributing 
on average between one-third and one-half of the t ~ t a I . * * ~ ~ . ' ~  Although these obser- 
vations raise the possibility that hepatic EPO mRNA is not as efficiently translated 
into an increase in serum EPO levels as renal EPO mRNA, a more obvious 
explanation for this discrepancy became apparent when it was found that the 
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expression of EPO mRNA in the liver is reduced following bilateral nephrectomy.” 
Therefore, at least in adult rats, experiments in bilaterally nephrectomized animals 
have so far probably underestimated the contribution of the liver to EPO produc- 
tion. In humans the precise hepatic potential for EPO formation remains unknown. 
The anemia of chronic renal disease is characterized by inappropriately low serum 
EPO levels,17 clearly indicating that extrarenal sites do not fully compensate for 
loss of the renal production capacity of the hormone. On the other hand, under 
conditions of severe hypoxia, marked elevations of serum EPO can be found in 
patients with chronic renal f a i l ~ r e , l * * ~ ~  including anephric individuals,20 suggesting 
that these elevations reflect a considerable hepatic potential for EPO production. 
It might be possible that hepatic expression of EPO is impaired in some patients 
with chronic renal disease, as seen after bilateral nephrectomy in rodents. How- 
ever, rats rendered chronically uremic by subtotal nephrectomy were found to 
become anemic, although the hepatic EPO mRNA response to severe hypoxia 
was unchanged.16 It is more likely, therefore, that anemia develops once renal 
EPO formation is impaired, because the sensitivity of the liver towards hypoxia 
is less than that of the kidneys, so that erythropoiesis is maintained at a lowered 
set point.21 In fact, when EPO mRNA accumulation was investigated in rats 
exposed to graded degrees of hypoxic hypoxia or anemia, the contribution of the 
liver to the total EPO mRNA was lower under moderate than under severe stimu- 
lat ion .* 
Although it would appear that the liver responds to anemic and hypoxic hypoxia 
in a principally similar manner to that of the kidneys, differences exist. Most 
importantly it was inferred from experiments with transgenic mice that different 
regulatory elements of the EPO gene may affect the oxygen-dependent response 
in these organs.22 Furthermore, a variety of external factors have been suggested 
to affect renal and hepatic EPO production differently. Interestingly in this respect, 
Beru et a/. observed that cobalt, which consistently stimulates EPO mRNA accu- 
mulation in kidneys, induces hepatic EPO mRNA accumulation only in some, but 
not in all animals.23 Moreover, protein deprivation was reported to diminish EPO 
production in unoperated rats,24 but had no effect or the effect of increased EPO 
production in anephric  rat^.^^,*^ Conversely, androgens increase the rate of erythro- 
poietin production in unoperated rats,27 but do not significantly change that of 
anephric ones.28 Finally, apart from systemic hypoxia, several types of hepatic 
injury have been reported to markedly stimulate EPO production by the liver. 
Thus, serum EPO levels in hypoxic bilaterally nephrectomized rats were found 
to be considerably higher following the induction of liver injury by either partial 
hepatectomy, administration of carbon tetrachloride, or ligation of the common 
bile d ~ ~ t . ~ ~ . ~ ~  Similarly, hematocrit values in anephric patients have been reported 
to increase during episodes of hepatitis.30 It has been suggested that increased 
hepatic EPO formation under these conditions is related to regeneration of liver 
tissue, but further work will be required to define the cellular sites and mechanisms 
of this increased production. 
CELLULAR SITES OF EPO FORMATION IN THE LIVER 
The liver comprises a variety of different cell types that can be roughly subdi- 
vided into parenchymal cells (hepatocytes) and nonparenchymal cells (including 
Kupffer cells, endothelial cells, and connective tissue cells). Among these different 
cells, it has for a long time been suggested that both Kupffer cells and hepatocytes 
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produce EPO. The evidence in favor of Kupffer cells includes correlations between 
reticuloendothelial hyperplasia and increased EPO production under certain exper- 
imental settings3' and the observation that Kupffer cells in the whole liver and 
in mixed liver cultures sequestered immunofluorescent antibodies raised against 
partially purified EP0.'3.32 Furthermore, it was proposed that Kupffer cells in 
culture secrete EP0.j3 On the other hand, elevated levels of EPO were found in 
plasma, urine, and tumor extracts of hepatocellular carcinoma  patient^,^^,^' and 
more recently two human hepatoma cell lines were reported to produce EPO in 
uitro (see be lo^).^^.^' Any conclusion from these findings, however, as to the 
physiological role of hepatocytes for EPO formation remained difficult, in particu- 
lar because renal cell carcinomas, which are considered to be derived from renal 
tubularcells, have also been shown to express EP0,j8 whereas most of the available 
evidence indicates that EPO is normally produced by peritubular  cell^.^^-^' 
More definite evidence for the role of hepatocytes and other liver cells in EPO 
production has recently been obtained by in situ hybridization and cell fractionation 
experiments. Thus, using in situ hybridization, Koury ef al. and Schuster et al. 
demonstrated that most of the cells expressing EPO mRNA in mouse or rat liver 
are in fact h e p a t o ~ y t e s . ~ ~ , ~ ~  However, about 20% of cells expressing EPO mRNA 
had a nonepithelial morphology and were located in or adjacent to the sinusoidal 
spaces, thus indicating that besides parenchymal cells at least one type of nonpa- 
renchymal liver cells also produces EPO. Similar conclusions were obtained from 
the measurement of EPO mRNA in isolated liver cells separated by different 
protocols, which also showed that EPO mRNA is normally present in both hepato- 
cytes and nonparenchymal cells. Although somewhat variable results were re- 
ported as to whether the abundance of EPO mRNA per unit total RNA in nonparen- 
chymal cells is lower$3 similar$4 or highep5 than in hepatocytes, two studies 
concluded that when quantitative differences in the content of total RNA per cell 
and the cell number per liver are considered, the nonparenchymal cells do not 
appear to contribute more than about 5% to the total EPO mRNA in the liver of 
both hypoxic juvenile'"' and anemic-hypoxic adult rats.43 Whether the relative 
contribution of both cell populations may vary under certain conditions, and if 
the nonparenchymal cells producing EPO are in fact Kupffer cells, remains to be 
clarified. Interestingly, in transgenic mice, showing oxygen-dependent expression 
of a human EPO transgene in liver, but not in kidneys, transgenic human EPO 
mRNA was expressed only in hepatocytes and not in nonparenchymal cells, 
suggesting that the expression of EPO in these cell types may be regulated differ- 
ently .42 
IN VITRO MODELS FOR HEPATIC EPO FORMATION 
Tissue culture systems derived from liver cells have not only been used in 
attempts to identify the cells producing EPO but also to facilitate studies on the 
cellular mechanisms of the oxygen-dependent control of the hormone. In mixed 
fetal liver cell cultures an increased secretion of erythropoietic bioactivity has 
been observed upon reduction of the oxygen t e n ~ i o n . ~ ~ . ~ '  These observations 
provided the first evidence that oxygen-sensing mechanisms can be retained in 
cultured liver cells, but the cell type responsible for this secretion and possible 
interactions of different cells were not identified. An alternative approach has 
been the study of EPO formation by the two human hepatoma cell lines HepG2 
and Hep3B. Following the observation by Goldberg et al. that these cell lines 
54 ANNALS NEW YORK ACADEMY OF SCIENCES 
0.1.25 2.5 5 9 -18 h 
FIGURE 2. Autoradiograph of an RNase protection assay for EPO mRNA using total RNA 
(100 pg) from isolated juvenile rat hepatocytes in primary culture. Hepatocytes were isolated 
by a two-stage in siru perfusion of the liver with chelating agents and co l l agena~e .~~  Following 
isolation, cells were preincubated for 4 hours at 40% oxygen in medium containing 10% 
fetal calf serum. They were then refed serum-free culture medium and exposed to 3% oxygen 
for up to 18 hours. Note that reduction of the oxygen tension led to a time-dependent 
accumulation of EPO mRNA; no increase was observed in cultures maintained at 40% 
oxygen for identical time periods. 
express EPO mRNA and secrete immuno- and bioreactive EPO in an oxygen- 
dependent fa~hion,~’ these cells have been widely used for studies on the cellular 
signal transduction and the control of the EPO gene, and have thereby undoubtedly 
allowed major progress in EPO research. Nevertheless, because it is unknown if 
characteristics of EPO production by these cell lines are influenced by their malig- 
nant transformation, we felt that it remains desirable to study the production of 
EPO also in those cells that are physiologically producing the hormone in uiuo. 
In view of the above-mentioned evidence that in juvenile rats hepatocytes are the 
primary site of EPO mRNA expression in uiuo, we have therefore studied the 
expression of EPO mRNA in primary cultures of juvenile rat hepatocytes. 
EXPRESSION OF EPO mRNA IN ISOLATED HEPATOCYTES 
To assess the ability of isolated hepatocytes to modulate the expression of 
EPO in an oxygen-dependent fashion, hepatocytes were isolated from normoxic 
animals and incubated in uitro at different oxygen tensions. Immediately after 
isolation, cells were first incubated for 4 hours in the presence of 10% serum to 
allow cell attachment at ambient or elevated oxygen pressure (20-40% 0,). During 
this preincubation period average EPO mRNA concentrations in isolated hepato- 
cytes remained either constant (20% 0,) or declined to very low levels (40% 0,). 
After the 4-hour period, cells were refed a serum-free medium, and when they 
were then exposed to low oxygen pressure (3% O,), we found a time-dependent 
accumulation of EPO mRNA, as shown in FIGURE 2. By contrast, EPO mRNA 
levels remained low upon further exposure to 40% oxygen. The hypoxia-induced 
increase in EPO mRNA levels was detectable as early as 1.25 hours after changing 
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the composition of the gas inflow to the incubators and reached maximal values 
between 2.5 and 5 hours. Thereafter EPO mRNA levels declined, but nevertheless 
remained elevated for at least 18 hours as compared to incubation at 20 or 40% 
oxygen. Thus the time course of EPO mRNA accumulation in isolated hepatocytes 
in uitro resembles that of hepatic EPO mRNA accumulation in uiuo, where an 
initial peak is also followed by partial down-regulation, despite continued hyp- 
oxic exposure.a 
Further experiments indicated that the hypoxia-induced rise in EPO mRNA 
levels in isolated hepatocytes is specific, because the rates of total RNA synthesis, 
as determined by [3H]uridine incorporation, decline with decreasing oxygen ten- 
sion, as illustrated in FIGURE 3. Thus it appears possible that the level of EPO 
mRNA at a given oxygen tension results from a balance between specific expres- 
sion of the EPO gene and nonspecific deterioration of cellular functions. This 
might explain why EPO mRNA concentrations in cells incubated at oxygen concen- 
Total RNA synthesis 
1 
I- 
35 -l 
1 2 3 4 5  20 
oxygen concentration (“h) 
FIGURE 3. Rates of total RNA synthesis (upper panel) and accumulation of EPO mRNA 
(lower panel) in isolated juvenile rat hepatocytes. Following a 4-hour preincubation period 
(see legend of FIG. 2), cells were incubated for 18 hours at varying oxygen tensions. Rates 
of total RNA synthesis were determined by measurement of [’Hluridine incorporation into 
trichloroacetic acid-insoluble material during the final 2.5 hours of incubation. EPO mRNA 
was measured by RNase protection and is expressed in arbitrary units derived from the 
comparison with an external standard that was coanalyzed on each gel. EPO mRNA levels 
in cultures incubated at 1% and 2% oxygen were significantly lower than those in parallel 
cultures of the same cell preparation that were incubated at 3% oxygenM 
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FIGURE 4. EPO mRNA accumulation in isolated juvenile rat hepatocytes incubated for 
18 hours at 20% oxygen in the presence of CoCl,, MnCI,, and NiCI, (closed symbols) and 
in parallel control cultures from the same cell preparations incubated at 3% oxygen in the 
absence of metals (open symbols). A slight, albeit significant increase in EPO mRNA as 
compared to cultures incubated at 20% oxygen in the absence of metals was seen with 50 
pM CoClz and 400 pM NiCI,, but overall, no marked stimulation of EPO mRNA expression 
could be induced, whereas hypoxic exposure of cells consistently increased EPO mRNA 
levels. EPO mRNA was measured by RNase protection and is expressed in arbitrary units 
derived from comparison with an external standard (values are means 2 SE from independent 
experiments, n = 4 for 50 pM CoClz and 3 for all other points).M 
trations below 3% were slightly reduced. Independent of the quantitative relation- 
ship between oxygen availability and EPO mRNA levels, the EPO mRNA response 
to a reduction in oxygen tension clearly indicates that regulation of EPO production 
can occur by way of intrinsic oxygen-sensing mechanisms, and does not essentially 
depend on external signals or intact tissue structure, although both may modulate 
the expression in uiuo. That hepatocytes are able to directly sense the oxygen 
tension is in accordance with the results of in situ hybridization experiments, 
which showed preferential expression of EPO mRNA in perivenous hepato- 
cytes of the liver lobule, that is, those areas where local oxygen tensions are 
lowest. 
Besides hypoxia, certain divalent metals such as CoCI, MnCI, or NiCl have 
been shown to stimulate EPO production in uiuo and in hepatoma cells. Based 
on a series of elegant experiments in Hep3B cells, Goldberg et al. have proposed 
that this stimulation might occur by way of replacement of a central iron atom in 
a putative heme protein operating as the oxygen sensor molecule, so that the 
incorporation of these metals mimicks a deoxyconfirmation of this heme protein.48 
In view of this hypothesis, we have investigated the effect of CoCI, NiCl, and 
MnCl on EPO mRNA levels in isolated hepatocytes incubated at ambient oxygen 
pressure for 18 hours. However, as illustrated in FIGURE 4, addition of these 
metals did not lead to a major increase of EPO mRNA levels. A slight, albeit 
significant elevation, compared to parallel cultures incubated at 20% O2 in the 
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absence of metals, was observed with 50 pM CoCl and 400 pM NiCI, but in 
neither case did the EPO mRNA concentrations exceed 7% of the concentration 
in parallel cultures incubated at low oxygen pressure (3% 02). The failure of 
CoCl to stimulate EPO expression more markedly in isolated hepatocytes is 
in accordance with previous studies in mixed fetal liver cells, in which hypoxia, 
but not CoCI, stimulated EPO p r o d ~ c t i o n , ~ ~  and with experiments performed 
in v im,  in which cobalt was a less consistent stimulus of hepatic EPO mRNA 
accumulation than h y p o ~ i a . ~ ~  One reason for the inconsistent effect of divalent 
metals on the expression of EPO may be that the turnover rate of a putative 
heme protein is variable, depending on the model investigated. Thus it appears 
possible that in isolated hepatocytes the turnover rate is significantly lower 
than in hepatoma cells, so that no efficient incorporation of divalent metals 
occurs. On the other hand we have no positive evidence at present that the 
oxygen sensing that governs the expression of EPO in hepatocytes occurs by 
way of a heme molecule. 
Independent of how changes in the oxygen availability of hepatocytes are 
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FIGURE 5. EPO mRNA accumulation in isolated juvenile rat hepatocytes incubated for 
18 hours at 20% oxygen in the presence of “second messengers” or agonists (closed symbols) 
and in parallel control cultures from the same preparation incubated at 3% oxygen in the 
absence of agents. The substances tested were (a) permeable analogues of CAMP and cGMP; 
(b) forskolin, which was used to stimulate adenylate cyclase; (c) 5‘-N-ethylcarboxy- 
amidoadenosine (NECA) or N-cyclohexyladenosine (CHA), which was used to stimulate 
adenosine receptors (A1 and A2, respectively); and (d) phorbol 12-myristate 13-acetate 
(PMA), which was used to stimulate protein kinase C. None of the substances tested led 
to a significant increase of EPO mRNA levels as compared to parallel cultures incubated 
at 20% oxygen in the absence of agents. EPO mRNA was measured by RNase protection 
and is expressed in arbitrary units derived from comparison with an external standard (values 
are mean 5 SE from independent experiments, n = 3).44 
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sensed, the question arises as to how the signal emerging from a putative 
sensor molecule is transduced into a rise of EPO mRNA. In other experimental 
models, such as mixed fetal liver cells, for example, the cAMP pathway has 
been suggested to mediate the induction of EPO e x p r e ~ s i o n . ~ ~ . ~ ~  We have 
therefore tested whether the rise in EPO in isolated hepatocytes that occurs 
upon hypoxic incubation could be mimicked by activation of classical second 
messenger pathways. To this end, hepatocytes were incubated at ambient 
oxygen pressure in the presence of membrane-permeable analogues of cAMP 
and cGMP, in the presence of two adenosine receptor agonists, o r  in the 
presence of the phorbol ester PMA, which was used to stimulate protein kinase 
C. As illustrated in FIGURE 5 ,  however, addition of none of these substances 
led to a significant increase of EPO mRNA levels. 
SUMMARY 
Several lines of evidence indicate that the liver is the predominant production 
site for EPO during the early stages of development. Moreover, in adults, it may 
contribute significantly to EPO production in some species. Independent of age 
hepatocytes are the major cellular sites of EPO gene expression in the liver, but 
quantitatively less significant expression also occurs in at least one additional type 
of nonparenchymal cell. Although some indirect evidence suggests that these 
nonparenchymal cells producing EPO may be Kupffer cells, their identity remains 
to be clarified. 
Regarding the mechanisms of the adaptation of hepatic EPO production to 
changes in oxygen availability in the organism, experiments with isolated perfused 
livers, mixed liver cell cultures, hepatoma cells, and, more recently, isolated 
hepatocytes have provided evidence that inherent cellular oxygen-sensing mecha- 
nisms exist and that external factors are not essential. The use of hepatoma cells 
has allowed investigation of these cellular mechanisms of oxygen-dependent gene 
control, and further studies in nontransformed hepatocytes may complement 
these studies. 
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DISCUSSION OF THE PAPER 
JAIME CARO (Thomas Jefferson University, Philadelphia, PA): Did you inject 
any animals of the same age and size as the animals from which you obtained 
hepatic cells for culture with cobalt, and did you see any induction? 
K.-U. ECKARDT (University of Regensburg, Regensburg, Germany): We 
haven't studied this systematically so far. Your question is important because 
there is some evidence from Dr. Goldwasser's group that cobalt does not pro- 
vide a consistent stimulus for hepatic erythropoietin mRNA accumulation. 
We have done a few animals, and we have seen an induction, but we haven't 
quantified it exactly. So I don't know whether the stimulation is a consistent 
phenomenon. 
CHAIRMAN EUGENE GOLDWASSER (The University of Chicago, Chicago, IL): 
Wouldn't it be better in trying to determine the specificity of the inhibitors of 
PKC or of protein kinases to use poly A plus RNA rather than total RNA? I ask 
this because you may be having a differential effect on message transcription, and 
all the ribosomal RNA in there will bias it.  
ECKARDT: Yes, this might be a very good suggestion. Clearly the specificity 
of such components is very difficult to determine. I think that the measurement 
of total RNA synthesis is a good parameter for assessing totally unspecific effects 
on cellular function. Nevertheless, with this kind of study we can only try to point 
to mechanisms that may be important, and that may either be only a very small 
link, or may be one of the central events. To figure this out with whole cell 
experiments, of course, is very difficult. 
JOACHIM FANDREY (University of Bonn, Bonn, Germany): We have had this 
discussion on the different effects of protein kinase C activators several times, 
and clearly these cells have a biphasic response. It would be very interesting to 
look at EPO mRNA levels at very early time points by competitive PCR. We 
have done this, looking at treatment with phorbol esters for 30 minutes and for 
one hour, and there is definitely no inhibition of erythropoietin production. We 
have used other stimuli, such as cytokines, and we saw inhibition within one hour. 
So I think that maybe these liver cells and HepG2 cells are different. With respect 
to the TPA response, we see the inhibition there at three hours. 
My question is regarding the cells. You showed this nice induction where you 
had two hypoxic periods, one after another. You showed that the response in the 
second one was lower. Have you tried to keep the cells in normoxia for 25 hours, 
which you needed for the first period, and then stimulated them? Is the lower 
response specific for the second stimulus, or is it because the cells are just older 
in culture? 
ECKARDT: Let me start with your second question. I'm not sure whether I 
understood you. What I showed on the first slide is that after a short period of 2-5 
hours there is a marked induction, and then under continuous hypoxic exposure the 
levels come down. What we did then in the next step, using the same conditions, 
was that we just interrupted the hypoxic exposure and then re-exposed the cells 
to hypoxia. There was a second increase under this situation. The peak was not 
as high as immediately after the beginning, but, again, definitely the cells increased 
the EPO messenger RNA. 
FANDREY: My question was, If you keep the cells normoxic for the same time 
period that you used for your first induction and then expose them to hypoxia, 
will they show the full response, or is the response lower? 
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ECKARDT: The response is not just as high as immediately after the isolation, 
but it is almost as high. Coming back to your first question regarding the kinetics 
with PMA, we have also done time course studies, at short intervals. We see a 
reduction of the erythropoietin messenger RNA at very short intervals, for exam- 
ple, after 1 hour. As you mentioned, I think this simply tells us that there are 
differences that may be important between hepatocyte primary cultures and hepa- 
toma cells. 
H. FRANKLIN BUNN (Brigham and Women's Hospital, Boston, MA):  I did not 
understand from the last diagram you presented what evidence you had that 
protein kinase C is involved in the hypoxic induction of EPO. 
ECKARDT: It is indirect insofar that inhibition of kinase activity with several 
kinase inhibitors abrogates the response. 
IVAN N. RICH (University of Ulm, Ulm, Germany): I have two simple questions 
with respect to the methodology. You mentioned at the beginning that one can 
separate hepatocytes by differential centrifugation. What is the level of contamina- 
tion in the hepatocyte population, and how long can you keep them in culture? 
Is there any proliferation in these cultures? 
ECKARDT: There is no proliferation under the conditions we are using. As you 
know, it is very difficult to get isolated hepatocytes to proliferate, and we haven't 
made any attempts in this direction because we were interested in establishing 
conditions for the study of freshly isolated cells after a short interval without 
adding any further complexity to the system by inducing cell proliferation and 
things like that. So under these conditions the cells are not growing, and I should 
add in this context that we are using serum-free conditions. During the first four 
hours the cells are incubated in the presence of serum to allow them to attach, 
but thereafter we use serum-free culture medium to study the expression of erythro- 
poietin. With regard to the contamination, clearly using differential centrifugation, 
we have some contamination, but the contamination under the conditions that we 
are using, with low speed centrifugation and other conditions of cell harvesting, 
I would say is no more than 5 percent. 
MARK J. KOURY (Vanderbilt University, Nashville, TN):  I have a question 
about the decline in erythropoietin RNA levels in the primary hepatocytes. You 
mentioned that there was a decline generally in mRNA. Did you look at specific 
messages of other genes, not just the decline in RNA? 
ECKARDT: We have looked at actin, but this may not be a very good choice 
because it is extremely stable. 
KOURY: It has a long half-life. 
ECKARDT: Yes, and this clearly does not change. 
KOURY: The other thing about this is that you use 3% oxygen, which is a 
level that would not induce much erythropoietin in Hep3B or HepG2 cells. Is 
that correct? 
ECKARDT: I have not done a comparison between hepatoma cells and hepato- 
cytes. Most people are using somewhat lower concentrations, and with 1% we 
do also get a response, but it is not as good as with 3 percent. 
KOURY: This all leads to the question, in my mind at least, about whether 
primary cells are correct as an in uivo representation. Do you think that there is 
a situation in which cells are producing EPO for only a short period of time and 
then that area is relieved of the hypoxia so that the cells are coming on and off 
in much the same way as Christmas tree lights come on and off. If that is so, then 
you must be into some very complex layers of control. I was wondering if you 
agree with this? 
ECKARDT: Yes, clearly this is an important consideration. You could argue 
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that although in the primary culture we have freshly isolated cells of a more or 
less homogeneous population, only some of these cells may produce erythropoietin 
when we look at them. I can’t exclude that possibility. 
WOLFGANG E. B. JELKMANN (University of Bonn, Bonn, Germany): One 
difference from the established hepatoma cell lines is that your preparation is not 
pure. Now if there are any macrophages in your preparations, substances like 
phorbol ester may induce production of interleukin-I, TNF, and reactive oxygen 
species. These products may lead to the inhibition of EPO production. 
ECKARDT: Yes, I can only agree with you. I mean that is a problem one cannot 
absolutely circumvent. As I said, we are using conditions that are very well 
established, which everybody uses to study hepatocytes in culture, which is a 
more or less pure culture, but still you may argue that a very few cells may have 
some effect in this context. With regard to the PMA effect, we have also studied 
it being aware of data presented by your group and other groups, showing that 
interleukin-I beta influences the expression, but we have not seen an effect on 
these isolated hepatocytes. So I am not very worried that the PMA effect is due 
to an interaction with other cells. 
FRANKLIN H. EPSTEIN (Harvard Medical School, Boston, M A ) :  The question 
of possible contamination might be answered if you did in situ hybridization, 
because most of the cells that were clearly hepatocytes might show the mRNA 
for EPO. I wonder whether, in fact, you have done that using these separated 
cell populations? 
ECKARDT: I think what you are addressing is whether the cells that we are 
studying and that show accumulation of erythropoietin mRNA in the dish are 
hepatocytes. I am pretty sure they are, because if we use conditions where there 
are more nonparenchymal cells, if we use a nonseparated cell preparation, the 
signal is absolutely identical to those obtained with a separated cell preparation. 
